Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy

Shahrokh F. Shariat, Robert S. Svatek, Wareef Kabbani, Jochen Walz, Yair Lotan, Pierre I. Karakiewicz, Claus G. Roehrborn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Study Type - Prognosis (case series) Level of Evidence 4 OBJECTIVE: To investigate the association of syndecan-1 expression with pathological features and disease progression in patients treated with radical prostatectomy (RP) as syndecan-1 plays a role in the regulation of cell proliferation, migration, and differentiation and its expression is altered in various malignancies. PATIENTS AND METHODS: Syndecan-1 immunostaining was performed on a tissue microarray containing cores from 232 consecutive patients treated with RP and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. Patients were categorized as having features of aggressive progression if they had evidence of metastases, an after progression prostate-specific antigen (PSA) doubling time of <10 months, and/or failure to respond to local salvage radiation therapy. Expression was defined as ≥ 10% cells staining for syndecan-1. RESULTS: Syndecan-1 was expressed in 86 patients (37.1%). Expression of syndecan-1 was associated with higher PSA levels (P = 0.004), higher pathological Gleason sum (P = 0.027) and lymph nodes metastases (P = 0.027). Patients with syndecan-1 expression were at significantly greater risk of PSA-progression after surgery (P = 0.034) in univariate but not in multivariate analysis. Patients with features of aggressive progression (n = 22) were more likely to express syndecan-1 than those with features of nonaggressive progression (63.6% vs 36.4%, P = 0.010). Patients with syndecan-1 expression were at significantly greater risk of aggressive progression after surgery (P = 0.005) in univariate but not in multivariate analysis. CONCLUSIONS: Expression of syndecan-1 was associated with established features of biologically aggressive prostate cancer and PSA-progression in univariate analysis. These findings suggest a role for syndecan-1 in prostate carcinogenesis and progression.

Original languageEnglish (US)
Pages (from-to)232-237
Number of pages6
JournalBJU International
Volume101
Issue number2
DOIs
StatePublished - Jan 2008

Fingerprint

Syndecan-1
Prostatectomy
Prostate-Specific Antigen
Prostatic Neoplasms
Multivariate Analysis
Neoplasm Metastasis
Salvage Therapy
Lymph Node Excision
Cell Movement
Disease Progression
Prostate
Cell Differentiation
Carcinogenesis
Adenocarcinoma

Keywords

  • Progression
  • Prostatic neoplasms
  • Radical prostatectomy
  • Stage
  • Syndecan-1

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. / Shariat, Shahrokh F.; Svatek, Robert S.; Kabbani, Wareef; Walz, Jochen; Lotan, Yair; Karakiewicz, Pierre I.; Roehrborn, Claus G.

In: BJU International, Vol. 101, No. 2, 01.2008, p. 232-237.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Svatek, Robert S. ; Kabbani, Wareef ; Walz, Jochen ; Lotan, Yair ; Karakiewicz, Pierre I. ; Roehrborn, Claus G. / Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. In: BJU International. 2008 ; Vol. 101, No. 2. pp. 232-237.
@article{a778f23986cd4d99a7c4b178e9532bb8,
title = "Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy",
abstract = "Study Type - Prognosis (case series) Level of Evidence 4 OBJECTIVE: To investigate the association of syndecan-1 expression with pathological features and disease progression in patients treated with radical prostatectomy (RP) as syndecan-1 plays a role in the regulation of cell proliferation, migration, and differentiation and its expression is altered in various malignancies. PATIENTS AND METHODS: Syndecan-1 immunostaining was performed on a tissue microarray containing cores from 232 consecutive patients treated with RP and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. Patients were categorized as having features of aggressive progression if they had evidence of metastases, an after progression prostate-specific antigen (PSA) doubling time of <10 months, and/or failure to respond to local salvage radiation therapy. Expression was defined as ≥ 10{\%} cells staining for syndecan-1. RESULTS: Syndecan-1 was expressed in 86 patients (37.1{\%}). Expression of syndecan-1 was associated with higher PSA levels (P = 0.004), higher pathological Gleason sum (P = 0.027) and lymph nodes metastases (P = 0.027). Patients with syndecan-1 expression were at significantly greater risk of PSA-progression after surgery (P = 0.034) in univariate but not in multivariate analysis. Patients with features of aggressive progression (n = 22) were more likely to express syndecan-1 than those with features of nonaggressive progression (63.6{\%} vs 36.4{\%}, P = 0.010). Patients with syndecan-1 expression were at significantly greater risk of aggressive progression after surgery (P = 0.005) in univariate but not in multivariate analysis. CONCLUSIONS: Expression of syndecan-1 was associated with established features of biologically aggressive prostate cancer and PSA-progression in univariate analysis. These findings suggest a role for syndecan-1 in prostate carcinogenesis and progression.",
keywords = "Progression, Prostatic neoplasms, Radical prostatectomy, Stage, Syndecan-1",
author = "Shariat, {Shahrokh F.} and Svatek, {Robert S.} and Wareef Kabbani and Jochen Walz and Yair Lotan and Karakiewicz, {Pierre I.} and Roehrborn, {Claus G.}",
year = "2008",
month = "1",
doi = "10.1111/j.1464-410X.2007.07181.x",
language = "English (US)",
volume = "101",
pages = "232--237",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy

AU - Shariat, Shahrokh F.

AU - Svatek, Robert S.

AU - Kabbani, Wareef

AU - Walz, Jochen

AU - Lotan, Yair

AU - Karakiewicz, Pierre I.

AU - Roehrborn, Claus G.

PY - 2008/1

Y1 - 2008/1

N2 - Study Type - Prognosis (case series) Level of Evidence 4 OBJECTIVE: To investigate the association of syndecan-1 expression with pathological features and disease progression in patients treated with radical prostatectomy (RP) as syndecan-1 plays a role in the regulation of cell proliferation, migration, and differentiation and its expression is altered in various malignancies. PATIENTS AND METHODS: Syndecan-1 immunostaining was performed on a tissue microarray containing cores from 232 consecutive patients treated with RP and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. Patients were categorized as having features of aggressive progression if they had evidence of metastases, an after progression prostate-specific antigen (PSA) doubling time of <10 months, and/or failure to respond to local salvage radiation therapy. Expression was defined as ≥ 10% cells staining for syndecan-1. RESULTS: Syndecan-1 was expressed in 86 patients (37.1%). Expression of syndecan-1 was associated with higher PSA levels (P = 0.004), higher pathological Gleason sum (P = 0.027) and lymph nodes metastases (P = 0.027). Patients with syndecan-1 expression were at significantly greater risk of PSA-progression after surgery (P = 0.034) in univariate but not in multivariate analysis. Patients with features of aggressive progression (n = 22) were more likely to express syndecan-1 than those with features of nonaggressive progression (63.6% vs 36.4%, P = 0.010). Patients with syndecan-1 expression were at significantly greater risk of aggressive progression after surgery (P = 0.005) in univariate but not in multivariate analysis. CONCLUSIONS: Expression of syndecan-1 was associated with established features of biologically aggressive prostate cancer and PSA-progression in univariate analysis. These findings suggest a role for syndecan-1 in prostate carcinogenesis and progression.

AB - Study Type - Prognosis (case series) Level of Evidence 4 OBJECTIVE: To investigate the association of syndecan-1 expression with pathological features and disease progression in patients treated with radical prostatectomy (RP) as syndecan-1 plays a role in the regulation of cell proliferation, migration, and differentiation and its expression is altered in various malignancies. PATIENTS AND METHODS: Syndecan-1 immunostaining was performed on a tissue microarray containing cores from 232 consecutive patients treated with RP and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. Patients were categorized as having features of aggressive progression if they had evidence of metastases, an after progression prostate-specific antigen (PSA) doubling time of <10 months, and/or failure to respond to local salvage radiation therapy. Expression was defined as ≥ 10% cells staining for syndecan-1. RESULTS: Syndecan-1 was expressed in 86 patients (37.1%). Expression of syndecan-1 was associated with higher PSA levels (P = 0.004), higher pathological Gleason sum (P = 0.027) and lymph nodes metastases (P = 0.027). Patients with syndecan-1 expression were at significantly greater risk of PSA-progression after surgery (P = 0.034) in univariate but not in multivariate analysis. Patients with features of aggressive progression (n = 22) were more likely to express syndecan-1 than those with features of nonaggressive progression (63.6% vs 36.4%, P = 0.010). Patients with syndecan-1 expression were at significantly greater risk of aggressive progression after surgery (P = 0.005) in univariate but not in multivariate analysis. CONCLUSIONS: Expression of syndecan-1 was associated with established features of biologically aggressive prostate cancer and PSA-progression in univariate analysis. These findings suggest a role for syndecan-1 in prostate carcinogenesis and progression.

KW - Progression

KW - Prostatic neoplasms

KW - Radical prostatectomy

KW - Stage

KW - Syndecan-1

UR - http://www.scopus.com/inward/record.url?scp=37349122445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349122445&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.07181.x

DO - 10.1111/j.1464-410X.2007.07181.x

M3 - Article

VL - 101

SP - 232

EP - 237

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -